{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:26:26Z","timestamp":1783743986290,"version":"3.55.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T00:00:00Z","timestamp":1714262400000},"content-version":"am","delay-in-days":363,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ando.2023.03.005","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T12:49:59Z","timestamp":1679489399000},"page":"346-350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Immune checkpoint inhibitor-related thyroid dysfunction"],"prefix":"10.1016","volume":"84","author":[{"given":"Fr\u00e9d\u00e9ric","family":"Illouz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Briet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Rodien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2023.03.005_bib0275","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ando.2023.03.005_bib0280","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"de Filette","year":"2019","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.ando.2023.03.005_bib0285","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2023.03.005_bib0290","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(16)30126-7","article-title":"Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate064): an open-label, randomised, phase 2 trial","volume":"17","author":"Weber","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ando.2023.03.005_bib0295","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ando.2023.03.005_bib0300","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.3390\/cancers13081944","article-title":"Graves\u2019 disease during immune checkpoint inhibitor therapy (a case series and literature review)","volume":"13","author":"Peiffert","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ando.2023.03.005_bib0305","first-page":"2087525","article-title":"Treatment of ipilimumab induced Graves\u2019 disease in a patient with metastatic melanoma","volume":"2016","author":"Azmat","year":"2016","journal-title":"Case Rep Endocrinol"},{"key":"10.1016\/j.ando.2023.03.005_bib0310","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000464285","article-title":"Tremelimumab-induced graves hyperthyroidism","volume":"6","author":"Gan","year":"2017","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.ando.2023.03.005_bib0315","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab","volume":"101","author":"de Filette","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.03.005_bib0320","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ando.2023.03.005_bib0325","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/cen.13483","article-title":"Endocrinopathies with use of cancer immunotherapies","volume":"88","author":"Villa","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2023.03.005_bib0330","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/cen.13297","article-title":"Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4and programmed death receptor protein-1 inhibitors in the treatment of melanoma","volume":"86","author":"Morganstein","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2023.03.005_bib0335","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms","volume":"102","author":"Delivanis","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.03.005_bib0340","doi-asserted-by":"crossref","first-page":"e3704","DOI":"10.1210\/clinem\/dgab263","article-title":"Thyroid immune-related adverse events following immune checkpoint inhibitor treatment","volume":"106","author":"Muir","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.03.005_bib0345","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1634\/theoncologist.2017-0375","article-title":"Incidence of thyroid function test abnormalities in patients receiving immune-checkpoint inhibitors for cancer treatment","volume":"23","author":"Patel","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.ando.2023.03.005_bib0350","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1089\/thy.2020.0075","article-title":"Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2023.03.005_bib0355","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.gendis.2017.11.002","article-title":"Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma","volume":"5","author":"Angell","year":"2018","journal-title":"Genes Dis"},{"key":"10.1016\/j.ando.2023.03.005_bib0360","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/cyt.13202","article-title":"Lymphocytic thyroiditis is a cytopathological feature of nivolumab-induced thyroid dysfunction","volume":"34","author":"Bakht","year":"2023","journal-title":"Cytopathology"},{"key":"10.1016\/j.ando.2023.03.005_bib0365","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2023.03.005_bib0370","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2147\/EB.S277760","article-title":"Neuro-ophthalmic complications of immune checkpoint inhibitors: a systematic review","volume":"12","author":"Yu","year":"2020","journal-title":"Eye Brain"},{"key":"10.1016\/j.ando.2023.03.005_bib0375","doi-asserted-by":"crossref","first-page":"e220024","DOI":"10.1530\/ETJ-22-0024","article-title":"Unexpected cure of a toxic nodule in a multinodular goiter induced by immune checkpoint inhibitors: a case report","volume":"11","author":"Dupuis","year":"2022","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.ando.2023.03.005_bib0380","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ando.2023.03.005_bib0385","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ando.2018.07.007","article-title":"Expert opinion on thyroid complications in immunotherapy","volume":"79","author":"Illouz","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.ando.2023.03.005_bib0390","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1210\/jc.2014-4560","article-title":"Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies","volume":"100","author":"Orlov","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.03.005_bib0395","doi-asserted-by":"crossref","first-page":"e251857","DOI":"10.1136\/bcr-2022-251857","article-title":"Progressive loss of the thyroid tissue integrity visualised by serial CT scans","volume":"15","author":"Koyama","year":"2022","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.ando.2023.03.005_bib0400","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1530\/EJE-10-0833","article-title":"Thyroid autoimmunity ophthalmopathy related to melanoma biological therapy","volume":"164","author":"Min","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2023.03.005_bib0405","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3109\/01676830.2014.949792","article-title":"Thyroid-like ophthalmopathy in a euthyroid patient receiving ipilimumab","volume":"33","author":"McElnea","year":"2014","journal-title":"Orbit"},{"key":"10.1016\/j.ando.2023.03.005_bib0410","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/IOP.0000000000000033","article-title":"Ipilimumab-induced orbital inflammation resembling graves disease with subsequent development of systemic hyperthyroidism from CTLA-4 receptor suppression","volume":"30","author":"Borodic","year":"2014","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.ando.2023.03.005_bib0415","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000485742","article-title":"Severe inflammatory ophthalmopathy in a euthyroid patient during nivolumab treatment","volume":"7","author":"Campredon","year":"2018","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.ando.2023.03.005_bib0420","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/bcr-2016-214603","article-title":"A rare case of thyroid storm","volume":"2016","author":"McMillen","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.ando.2023.03.005_bib0425","first-page":"140092","article-title":"A novel melanoma therapy stirs up a storm: ipilimumab-induced thyrotoxicosis","volume":"2015","author":"Yu","year":"2015","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.ando.2023.03.005_bib0430","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40425-017-0213-x","article-title":"Nivolumab induced myxedema crisis","volume":"5","author":"Khan","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ando.2023.03.005_bib0435","doi-asserted-by":"crossref","first-page":"e250696","DOI":"10.1136\/bcr-2022-250696","article-title":"Thyroid storm induced by combined nivolumab and ipilimumab immunotherapy in advanced non-small cell lung cancer","volume":"15","author":"Kataoka","year":"2022","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.ando.2023.03.005_bib0440","first-page":"8855943","article-title":"Myxedema Coma: a life-threatening condition in patients using pembrolizumab","volume":"2020","author":"Gummalla","year":"2020","journal-title":"Case Rep Endocrinol"},{"key":"10.1016\/j.ando.2023.03.005_bib0445","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/ERC-18-0320","article-title":"French Endocrine Society Guidance on endocrine side effects of immunotherapy","volume":"26","author":"Castinetti","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2023.03.005_bib0450","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/2326-6066.CIR-18-0613","article-title":"The impact of high-dose glucocorticoids on the outcome of immune-checkpoint inhibitor-related thyroid disorders","volume":"7","author":"Ma","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ando.2023.03.005_bib0455","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/cam4.1145","article-title":"Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists","volume":"6","author":"Illouz","year":"2017","journal-title":"Cancer Med"},{"key":"10.1016\/j.ando.2023.03.005_bib0460","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ando.2023.03.005_bib0465","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ando.2023.03.005_bib0470","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Immune checkpoint inhibitors: review and management of endocrine adverse events","volume":"21","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.ando.2023.03.005_bib0475","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"EUGOGO \u2020 The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2023.03.005_bib0480","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1089\/thy.2012.0205","article-title":"Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association","volume":"22","author":"Garber","year":"2012","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2023.03.005_bib0485","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ando.2018.07.008","article-title":"Expert opinion on pituitary complications in immunotherapy","volume":"79","author":"Briet","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.ando.2023.03.005_bib0490","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EC-18-0068","article-title":"Society for Endocrinology Endocrine Emergency guidance: acute management of the endocrine complications of checkpoint inhibitor therapy","volume":"7","author":"Higham","year":"2018","journal-title":"Endocr Connect"},{"key":"10.1016\/j.ando.2023.03.005_bib0495","doi-asserted-by":"crossref","first-page":"e1843","DOI":"10.1210\/clinem\/dgac059","article-title":"Association of antithyroid antibodies in checkpoint inhibitor-associated thyroid immune-related adverse events","volume":"107","author":"Muir","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.03.005_bib0500","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1111\/cas.13800","article-title":"Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab","volume":"109","author":"Kimbara","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ando.2023.03.005_bib0505","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2023.03.005_bib0510","doi-asserted-by":"crossref","DOI":"10.1007\/s12020-023-03323-9","article-title":"Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study","author":"Wu","year":"2023","journal-title":"Endocrine"},{"key":"10.1016\/j.ando.2023.03.005_bib0515","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3390\/cancers14040875","article-title":"Immune-related thyroiditis as a predictor for survival in metastatic renal cell carcinoma","volume":"14","author":"Sagie","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ando.2023.03.005_bib0520","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1080\/0284186X.2021.1958006","article-title":"Thyroid dysfunction and survival in cancer patients treated with immune checkpoint inhibitors: analyses from a large single tertiary cancer center database","volume":"60","author":"Percik","year":"2021","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ando.2023.03.005_bib0525","doi-asserted-by":"crossref","first-page":"e1375642","DOI":"10.1080\/2162402X.2017.1375642","article-title":"Development of thyroid dysfunction is associated with clinical response to PD-1blockade treatment in patients with advanced non-small cell lung cancer","volume":"7","author":"Kim","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ando.2023.03.005_bib0530","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ando.2023.03.005_bib0535","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ando.2023.03.005_bib0540","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1634\/theoncologist.2017-0133","article-title":"Immune-related adverse events as a biomarker in non-melanoma patients treated with programmed cell death 1 inhibitors","volume":"22","author":"Judd","year":"2017","journal-title":"Oncologist"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000342662300046X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000342662300046X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:55:01Z","timestamp":1757717701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000342662300046X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S000342662300046X"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2023.03.005","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitor-related thyroid dysfunction","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2023.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}